The goal of antiviral therapy for chronic hepatitis B is to prevent progression of the disease to cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death. This goal of improving quality of life and survival can be achieved by long-term viral suppression. But can antiviral therapy be reversed in patients who have progressed to cirrhosis? Many recent studies have reported confirming that cirrhosis can be reversed in some patients with cirrhosis with long-term antiviral therapy. Several studies have recently confirmed that long-term oral lamivudine for 1 and 3 years can result in improvements in necroinflammation in 56% and 57% of patients. However, once drug resistance occurs, the patient’s condition will deteriorate again. The use of entecavir for 144-316 weeks, etc. can lead to improvement in necroinflammation in 88% of patients. However, long-term use of oral antivirals carries the risk of developing resistance. It has been reported in the literature that the 5-year genotypic resistance rates for lamivudine and adefovir alone are as high as 80% and 29%, respectively, while the 5-year resistance rate for patients treated with entecavir for the first time is 1.2%. Therefore, in the choice of antiviral drugs, either a single drug with high efficacy and low resistance rate or a combination of two drugs (some reports such as lamivudine combined with adefovir also have low resistance rates) are needed. This was agreed upon at the 2009 European Annual Meeting on the Liver (EASL). In my clinical practice for many years, after long-term use of antiviral drugs in patients with cirrhosis, the imaging of cirrhosis does also manifest itself in some patients.